Extended Data Fig. 3: Elovl1-deficient CD8+ T cells increased activity upon anti-PD-1 treatment.
a, Elovl1 expression assessed by qRT-PCR (n=7) in vitro in sgNT or sgElovl1 OT-I T cells at day 7 from activation. Exact p value = 0.000001. b, Experimental design of Elovl1 in vivo validation in PDAC model. c, Liver to body weight ratio in an experimental model of PDAC liver metastasis. The mice were injected intrasplenic with KPC_OVA. Eight days later, they received sgNT or sgElovl1 OT-I T cells and started anti-PD-1 therapy the following day (n=5). d, SLAMF6 expression on OT-I T cells infiltrating PDAC primary tumour (n=5). e, Schematics of pmel-1 T cells ACT experiment. f, g, Tumour growth spider plots in B16F1 tumour-bearing mice injected with sgNT (f) or sgElovl1 (g) pmel-1 T cells (sgNT n=12, sgElovl1 n=11). h, Flow cytometry quantification of CD44+ CD62L+ (Tcm) in pmel-1 T cells infiltrating the spleen of B16F1-bearing mice (sgNT n=12, sgElovl1 n=11, two independent experiments). i–k, Flow cytometry quantification of PD-1 (i), TIGIT (j) and CD39 (k) in pmel-1 T cells infiltrating the primary tumour of B16F1-bearing mice (sgNT n=11, sgElovl1 n=8). (i) Exact p value = 0.000095. Data are presented as the mean ± s.e.m. Statistical significance was assessed by paired (a) or unpaired (c, h–k) two-tailed Student’s t-test and one-way ANOVA (d). Parts of this figure were created in BioRender. Mazzone, M. (2025) https://BioRender.com/ s90t255.
